Search
Immunovant Inc
IMVTAdd to Watchlist
38.620USD
-0.860-2.18%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.88BMarket Cap
LossP/E TTM
More Details of Immunovant Inc Company
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Immunovant Inc Info
Ticker SymbolIMVT
Company nameImmunovant Inc
IPO dateMay 14, 2019
CEOVenker (Eric)
Number of employees362
Security typeOrdinary Share
Fiscal year-endMay 14
Address320 West 37Th Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10018
Phone19175803099
Websitehttps://immunovant.com/
Ticker SymbolIMVT
IPO dateMay 14, 2019
CEOVenker (Eric)
Company Executives of Immunovant Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
782.05K
-0.97%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
122.85K
--
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
120.77K
+1.91%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
60.50K
+3.81%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
43.23K
-14.68%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
27.59K
+8.94%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
24.46K
-8.32%
Mr. Robert G. Susman
Mr. Robert G. Susman
Independent Director
Independent Director
--
--
Mr. Jacob (Jake) Bauer
Mr. Jacob (Jake) Bauer
Independent Director
Independent Director
--
--
Mr. Tiago Girao
Mr. Tiago Girao
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
782.05K
-0.97%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
122.85K
--
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
120.77K
+1.91%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
60.50K
+3.81%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
43.23K
-14.68%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
27.59K
+8.94%
FAQs
Who are the top five shareholders of Immunovant Inc?
The top five shareholders of Immunovant Inc are: Dr. Frank M. Torti, M.D.
How many institutions hold shares of Immunovant Inc (IMVT)?
As of 2026Q1, 478 institutions hold shares of Immunovant Inc, with a combined market value of approximately 112.99M, accounting for 55.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -342517.00.